Cargando…
Hurdles and delays in access to anti-cancer drugs in Europe
Demographic changes in the world population will cause a significant increase in the number of new cases of cancer. To handle this challenge, societies will need to adapt how they approach cancer prevention and treatment, with changes to the development and uptake of innovative anticancer drugs play...
Autores principales: | Ades, F, Zardavas, D, Senterre, C, de Azambuja, E, Eniu, A, Popescu, R, Piccart, M, Parent, F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263523/ https://www.ncbi.nlm.nih.gov/pubmed/25525460 http://dx.doi.org/10.3332/ecancer.2014.482 |
Ejemplares similares
-
Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA
por: Ades, Felipe, et al.
Publicado: (2017) -
Handling the Hurdles on the Way to Anti-tuberculosis Drug Development
por: Dalberto, Pedro F., et al.
Publicado: (2020) -
New generation of breast cancer clinical trials implementing molecular profiling
por: Zardavas, Dimitrios, et al.
Publicado: (2016) -
The past and future of breast cancer treatment—from the papyrus to individualised treatment approaches
por: Ades, Felipe, et al.
Publicado: (2017) -
Legislative hurdles to using traditional domestic livestock in rewilding programmes in Europe
por: Pérez-Barbería, F. Javier, et al.
Publicado: (2022)